2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W030796AR
    Lactisole (Standard) 150436-68-3
    Bisdemethoxycucurmin (Standard) is the analytical standard of Bisdemethoxycucurmin. This product is intended for research and analytical applications. Bisdemethoxycucurmin (Curcumin III), a curcuminoid, has antioxidant and antiinflammatory activities.
    Lactisole (Standard)
  • HY-W032013S1
    1-Octanol-d2 78510-02-8 98%
    1-Octanol-d2 is the deuterium labeled 1-Octanol. 1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC50 of 4 μM for native T-currents. 1-Octanol is a highly attractive biofuel with diesel-like properties.
    1-Octanol-d2
  • HY-W040329S2
    2'-Deoxyadenosine-d13 98%
    2'-Deoxyadenosine-d13 is deuterium labeled 2'-Deoxyadenosine (HY-W040329). 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer.
    2'-Deoxyadenosine-d13
  • HY-W040329S3
    2'-Deoxyadenosine-15N5,d13 98%
    2'-Deoxyadenosine-15N5,d13 is deuterium and 15N labeled 2'-Deoxyadenosine (HY-W040329). 2′-Deoxyadenosine is an adenine nucleoside that inhibits glucose-stimulated insulin release. 2′-Deoxyadenosine inhibits glucose-stimulated increases seen in islet cyclic AMP (cAMP) accumulation. 2'-Deoxyadenosine activates caspase-3 and promotes apoptosis. 2'-Deoxyadenosine inhibits the activity of S-adenosyl-L-homocysteine hydrolase (SAHH). 2'-Deoxyadenosine inhibits the growth of various cells. 2'-Deoxyadenosine has an anticancer effect on colon cancer.
    2'-Deoxyadenosine-15N5,d13
  • HY-W013061S10
    Propane-1,2,3-triyl tripalmitate-13C 98%
    Propane-1,2,3-triyl tripalmitate-13C is the 13C labeled Propane-1,2,3-triyl tripalmitate. Propane-1,2,3-triyl tripalmitate is an endogenous metabolite.
    Propane-1,2,3-triyl tripalmitate-13C
  • HY-10869
    OL-135 681135-77-3 98%
    OL-135 is a CNS penetrant, selective, and reversible of FAAH inhibitor. OL-135 exhibits analgesic activity.
    OL-135
  • HY-11085
    T-226296 331758-35-1 98%
    T-226296 is an oral active and selective melanin-concentrating hormone receptor antagonist with the IC50 values of 5.5 nM and 8.6 nM for human SLC-1 and rat SLC-1, respectively. T-226296 can be used for study of obesity and insulin resistance.
    T-226296
  • HY-12074
    Cazpaullone 914088-64-5 98%
    Cazpaullone is a glycogen synthase kinase-3 (GSK-3) inhibitor. Cazpaullone can activate pancreatic beta cell protection and replication. Cazpaullone can be used for the research of diabetes.
    Cazpaullone
  • HY-12104
    PF-514273 851728-60-4 98%
    PF-514273 is an orally active, selective antagonist for cannabinoid-1 receptor (CB1) with IC50 of 1 nM. PF-514273 reduces the food uptake in mice, and can be used for obesity research.
    PF-514273
  • HY-12735
    SCH 900822 1220894-09-6 98%
    SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes.
    SCH 900822
  • HY-12976
    DS-1558 1202575-67-4 98%
    DS-1558 is an orally active small molecule G protein-coupled receptor 40 agonist. DS-1558 not only increases the glucose-stimulated insulin secretion by glucagon like peptide-1 (GLP-1) but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats. DS-1558 is promising for research of type 2 diabetes.
    DS-1558
  • HY-14156
    11β-HSD1-IN-15 946398-78-3 98%
    11β-HSD1-IN-15 is an inhibitor of 11β-hydroxysteroid dehydrogenase type I (11β-HSD1). 11β-HSD1-IN-15 blocks the conversion of corticosterone to cortisol by binding to the active site of the 11β-HSD1 enzyme. 11β-HSD1-IN-15 can be used to investigate the role of 11β-HSD1 enzymes IN the development of metabolic syndrome, obesity, cognitive decline and type 2 diabetes.
    11β-HSD1-IN-15
  • HY-14747
    Piragliatin 625114-41-2 98%
    Piragliatin (RO4389620) is an activator for glucokinase, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy.
    Piragliatin
  • HY-14753
    Rosonabant 861151-12-4 98%
    Rosonabant is a selective antagonist for cannabinoid receptor (CB1 receptor), which reduces body weight and improves improves the risk of obesity-related cardiovascular metabolic diseases. Rosonabant exhibits adverse side effect, such as nausea and mental disorder.
    Rosonabant
  • HY-14771
    Imeglimin 775351-65-0 98%
    Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function.
    Imeglimin
  • HY-14902
    Tofogliflozin 903565-83-3 98%
    Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.
    Tofogliflozin
  • HY-15327
    1alpha, 25-Dihydroxy VD2-d6 216244-04-1 99%
    1alpha, 25-Dihydroxy VD2-d66 is a deuterated form of vitamin D.
    1alpha, 25-Dihydroxy VD2-d6
  • HY-15384
    Picoprazole 78090-11-6 98%
    Picoprazole is a specific inhibitor of H+/K+-ATPase with IC50 of 3.1±0.4 μM.
    Picoprazole
  • HY-16266
    JNJ-DGAT1-A 1092067-85-0 98%
    JNJ-DGAT1-A is a selective DGAT1 inhibitor. JNJ-DGAT1-A inhibits DGAT1 activity and TG synthesis.
    JNJ-DGAT1-A
  • HY-16708
    ZLN024 723249-01-2 98%
    ZLN024 is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1, AMPK α2β1γ1, AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC50s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.
    ZLN024
Cat. No. Product Name / Synonyms Application Reactivity